Duopharma Biotech Berhad (KLSE:DPHARMA)
Malaysia · Delayed Price · Currency is MYR 1.230
+0.020 (1.65%)
At close: Jun 10, 2026
Duopharma Biotech Berhad Stock Forecast
Stock Price Forecast
According to 5 analysts polled by S&P Global, Duopharma Biotech Berhad stock has a consensus rating of "Strong Buy" and an average price target of RM 1.69. The average 1-year stock price forecast is 37.40% higher than the current stock price, while the lowest is RM 1.61 (+30.89%) and the highest is RM 1.79 (+45.53%).
Price Target: RM 1.69 (+37.40%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Duopharma Biotech Berhad stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Nov '25 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Financial Forecast
Revenue This Year
1.02B
from 931.69M
Increased by 9.04%
Revenue Next Year
1.06B
from 1.02B
Increased by 4.49%
EPS This Year
0.11
from 0.09
Increased by 17.44%
EPS Next Year
0.11
from 0.11
Increased by 6.56%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is MYR.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 1.2B | ||
| Avg | 1.0B | ||
| Low | 935.0M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 23.7% | ||
| Avg | 9.0% | ||
| Low | 0.4% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 0.12 | ||
| Avg | 0.11 | ||
| Low | 0.10 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 26.5% | ||
| Avg | 17.4% | ||
| Low | 10.0% |